Literature DB >> 29123827

Ornithine transcarbamylase deficiency that developed at the age of 19 years with acute brain edema.

Hidenori Mitani1, Toshiaki Mochizuki1, Norio Otani1, Hiroyuki Tanaka1, Shinichi Ishimatsu1.   

Abstract

Case: A 19-year-old man had nausea, diarrhea, and general malaise the day before requesting emergency transport to his former primary physician. The patient became restless and had tonic seizures after admission. The patient was transferred to our hospital as there had been no improvement in his level of consciousness. On arrival, cranial computed tomography showed generalized swelling, and blood ammonia concentration was ≥500 μg/dL. After admission, seizures recurred continually despite careful monitoring and increased doses of sedatives and antiseizure drugs. Dilated pupils and a flat electroencephalogram were evident on day 4 of admission, and the patient died on day 11. Ornithine transcarbamylase deficiency was diagnosed at postmortem based on fractionation of blood and urine amino acids and orotic acid. Outcome: Urea cycle disorders need to be treated urgently to prevent irreversible neurological damage when accompanied by hyperammonemia.
Conclusion: In cases of hyperammonemia, early dialysis should be considered to reduce the ammonia level.

Entities:  

Keywords:  Endocrinology; metabolism

Year:  2016        PMID: 29123827      PMCID: PMC5667334          DOI: 10.1002/ams2.214

Source DB:  PubMed          Journal:  Acute Med Surg        ISSN: 2052-8817


  8 in total

1.  Long-term outcome and intervention of urea cycle disorders in Japan.

Authors:  Jun Kido; Kimitoshi Nakamura; Hiroshi Mitsubuchi; Toshihiro Ohura; Masaki Takayanagi; Masafumi Matsuo; Makoto Yoshino; Yosuke Shigematsu; Tohru Yorifuji; Mureo Kasahara; Reiko Horikawa; Fumio Endo
Journal:  J Inherit Metab Dis       Date:  2011-12-14       Impact factor: 4.982

2.  Coma, hyperammonemia, metabolic acidosis, and mutation: lessons learned in the acute management of late onset urea cycle disorders.

Authors:  Hari Iyer; Methu Sen; Chitra Prasad; C Anthony Rupar; Robert M Lindsay
Journal:  Hemodial Int       Date:  2012-01       Impact factor: 1.812

Review 3.  Brain imaging in urea cycle disorders.

Authors:  Andrea Gropman
Journal:  Mol Genet Metab       Date:  2010-02-13       Impact factor: 4.797

4.  Long-term treatment of girls with ornithine transcarbamylase deficiency.

Authors:  N E Maestri; S W Brusilow; D B Clissold; S S Bassett
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

5.  Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene.

Authors:  Saori Yamaguchi; Lisa L Brailey; Hiroki Morizono; Allen E Bale; Mendel Tuchman
Journal:  Hum Mutat       Date:  2006-07       Impact factor: 4.878

6.  Current strategies for the management of neonatal urea cycle disorders.

Authors:  M Summar
Journal:  J Pediatr       Date:  2001-01       Impact factor: 4.406

7.  Postictal transient hyperammonemia.

Authors:  Kuan-Ting Liu; Chen-San Su
Journal:  Am J Emerg Med       Date:  2008-03       Impact factor: 2.469

8.  Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.

Authors:  Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

  8 in total
  2 in total

1.  Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency.

Authors:  Koji Imoto; Masatake Tanaka; Takeshi Goya; Tomomi Aoyagi; Motoi Takahashi; Miho Kurokawa; Shigeki Tashiro; Masaki Kato; Motoyuki Kohjima; Yoshihiro Ogawa
Journal:  BMC Gastroenterol       Date:  2022-03-28       Impact factor: 3.067

Review 2.  Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.

Authors:  Yamir Islam; Andrew G Leach; Jayden Smith; Stefano Pluchino; Christopher R Coxon; Muttuswamy Sivakumaran; James Downing; Amos A Fatokun; Meritxell Teixidò; Touraj Ehtezazi
Journal:  Adv Sci (Weinh)       Date:  2021-03-15       Impact factor: 16.806

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.